Drugs / DHP1401
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03055741 | Dec 2016 → Feb 2019 | Alzheimer disease | Daehwa Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT04111341 | May 2016 → Oct 2017 | Sjogren syndrome | Chung Shan Medical University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DHP1401 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03055741 ↗ |
| Known as | Suan-Zao-Ren | “TCM Gan-Lu-Yin 6g in the morning TCM Jia-Wei-Xiao-Yao-San, Ye-Jiao-Teng, Suan-Zao-Ren 8g in the evening for 12 weeks” NCT04111341 ↗ |
| Route | Oral | “DHP1401: Total 500mg is orally administrated in two divided doses a day for 24 weeks” NCT03055741 ↗ |